CTIS.eu › Cities › Germany › Bielefeld
Bielefeld
Germany
141 total trials
66 recruiting
2024-520138-31-00
4
2026-06-01
Early-stage favorable classic Hodgkin lymphoma
2025-522091-84-00
4
2026-05-29
Merkel Cell Carcinoma
2025-523914-10-00
6
2026-04-30
Critical illness
2025-522403-17-00
5
2026-04-10
Nummular Dermatitis
2024-520101-39-00
5
2026-04-01
TROP2 NMR-positive advanced or metastatic non-squamous non-small cell
2024-516544-26-00
4
2026-03-30
acute ischemic stroke
2024-516356-18-00
5
2026-02-17
Atherosclerotic cardiovascular disease (ASCVD)
2024-520337-80-00
5
2026-01-07
Palmoplantar Pustulosis
2024-519494-19-00
5
2025-12-22
Nutritional and metabolic diseases
2022-500676-59-00
4
2025-12-18
EBV-positive nasopharyngeal carcinoma
2025-522718-22-00
4
2025-12-16
Gastroesophageal Adenocarcinoma
2025-520564-17-00
5
2025-10-16
Hidradenitis suppurativa (HS)
2025-521640-38-00
5
2025-10-16
Focal onset seizures or primary generalized tonic-clonic seizures.
2024-514974-39-00
5
2025-10-10
Developmental and Epileptic Encephalopathies (DEEs)
2023-509861-19-01
4
2025-09-30
Diffuse large B-cell lymphoma (DLBCL)
2024-517671-21-00
5
2025-09-30
Coronavirus Disease 2019 (COVID-19)
2024-517745-14-00
4
2025-09-24
Multiple Sclerosis Spasticity
2025-520519-14-00
5
2025-09-03
Atherosclerotic Cardiovascular Disease
2023-505758-17-00
4
2025-08-21
endocrine-responsive HER2-negative early breast cancer
2024-516633-12-00
5
2025-06-30
Locally advanced/ metastatic gastroesophageal junction and gastric can
2024-514937-39-00
5
2025-05-20
Dravet Syndrome
2023-508076-11-00
5
2025-04-01
Colon cancer staged T3-4 and/or nodal positive by CT and/or MRI scan w
2022-500574-34-00
4
2025-03-21
Waldenström’s Macroglobulinemia
2023-508813-18-00
4
2024-12-18
Refractory Focal Onset Epilepsy
Showing 25–48 of 141 trials